The workshop aimed at 1) identifying challenges associated with getting TNF-α inhibitors in the clinical setting for people with T1D, 2) establishing consensus on an optimal path for TNF-α inhibitors from phase 2 studies to phase 3 and FDA approval in people with stage 3 T1D, and 3) identifying commercial opportunities for TNF-α inhibitors. Here, TNF is linked to type 1 diabetes mellitus.